RLMD Jumps As Relmada Insider Buying Sparks Bullish Interest​

Relmada Therapeutics Inc. stocks have been trading up by 12.28 percent following pivotal positive clinical trial progress news

Weekly Update Sep 07 – Sep 11, 2026: On Sunday, September 13, 2026 Relmada Therapeutics Inc. stock [NASDAQ: RLMD] is trending up by 12.28%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Relmada Therapeutics is a micro-cap, clinical-stage CNS player with no revenue, deeply negative ROE (~-56%) and ROA (~-52%), and operating losses of ~$15M in the latest quarter. Cash burn (~$9.6M OCF in Q2) is material but funded by a recent ~$160M equity raise, leaving cash and investments of ~$218M, no debt, and an exceptional current ratio (~29x). Book value per share is $1.94 with a ~2.3x P/B, implying the market is pricing in meaningful pipeline optionality despite poor historical capital efficiency.

Technically, RLMD has shown a sharp, short-term momentum burst, moving from ~$4.07–4.10 to a $4.61 intraday high and closing near $4.57 on expanding volume, confirming aggressive buying interest. The dominant near-term trend is up, with a key actionable support level at ~$4.10 (recent consolidation and prior close). As long as price holds above $4.10 on a closing basis, upside scalps toward $4.75–5.00 are favored; a decisive break below $4.10 would signal momentum exhaustion and likely mean reversion.

More Breaking News

• Tenon Medical TNON Cleans Up Debt As Nasdaq Compliance Returns
• Zscaler Stock Jumps As Earnings Beat And AI Bets Impress Wall Street
• VEEA Stock Spikes On Heavy Volume As Traders Hunt Volatility
• BMNR Stock Slides As Heavy Losses Clash With Cash-Rich Balance Sheet

Recent insider purchases (CEO and CFO each buying 200,000 shares) are a strong governance and confidence signal, reinforced by additional Form 4 activity and ~11% price appreciation on solid volume. Participation in the Wells Fargo healthcare conference increases visibility versus broader Healthcare and Biotech indices, where RLMD still trades at a steep discount on EV vs. peer-stage pipelines. I view the risk/reward as favorable with a decisively Positive bias, near-term support at $4.10 and resistance/initial target at $5.25.

Quick Financial Overview

Relmada Therapeutics Inc. is trading in a tight but active range, with weekly data showing a push from roughly $4.09 to a $4.61 high and a recent close around $4.57. That nearly 11% jump came on the back of sizeable insider buying from the CEO and CFO, each purchasing 200,000 shares, suggesting management sees value near these levels. Intraday, a 5-minute candle with a $4.65 high and $4.295 low shows RLMD can move quickly inside the day, but still close strong near $4.52.

On the balance sheet, RLMD holds about $11.3M in cash and roughly $217.7M when including short-term investments, against total liabilities near $12.5M. A current ratio around 29 and zero long-term debt give the company meaningful financial flexibility for a clinical-stage name. Working capital of about $211.6M is sizable, but traders must balance that against ongoing cash burn.

The latest quarterly report shows a net loss of about $12.9M and operating cash outflow near $9.6M, standard for a development-stage biotech. Negative returns on equity and assets highlight that RLMD is not about current profits but about pipeline potential. With an enterprise value around $14.2M and price-to-book near 2.33, traders are paying a premium to book for optionality on NDV-01, sepranolone, and broader CNS and oncology assets.

Conclusion

Relmada Therapeutics Inc. is showing a classic short-term momentum-plus-catalyst setup that active traders look for. The stock has broken higher on insider buying, with the CEO and CFO stepping in for 200,000 shares each and price lifting toward the mid-$4s on that signal. Weekly and intraday charts confirm real participation but not blowout volume, which means RLMD can still be sensitive to new orders and headlines. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.”, and RLMD’s current action is a good example of why those elements matter so much in short-term trading.

Financially, RLMD carries strong liquidity and no debt, but it is still a loss-making, clinical-stage story with steady cash burn. That combination can produce sharp swings as sentiment flips between confidence in the pipeline and fear around funding and trial outcomes. The upcoming Wells Fargo healthcare conference, where management will highlight NDV-01 and sepranolone in one-on-one meetings, is an important near-term sentiment event that could impact both volume and volatility.

For traders, the key is to respect the risk-reward: a small enterprise value, heavy insider activity, and clear catalysts can drive explosive moves in both directions. As I tell my students when I see a setup like RLMD, “Insider conviction and clean balance sheets can light the fuse, but disciplined risk management decides who actually walks away with the profits.”

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.